Stock Buzzer: What’s Karyopharm Therapeutics Inc Downside After Today’s Huge Decline?

Stock Buzzer: What's Karyopharm Therapeutics Inc Downside After Today's Huge Decline?

The stock of Karyopharm Therapeutics Inc (NASDAQ:KPTI) is a huge mover today! About 123,272 shares traded hands. Karyopharm Therapeutics Inc (NASDAQ:KPTI) has risen 24.62% since March 8, 2016 and is uptrending. It has outperformed by 15.30% the S&P500.
The move comes after 6 months negative chart setup for the $346.72M company. It was reported on Oct, 11 by We have $8.30 PT which if reached, will make NASDAQ:KPTI worth $41.61M less.

Analysts await Karyopharm Therapeutics Inc (NASDAQ:KPTI) to report earnings on November, 14. They expect $-0.77 EPS, up 9.41% or $0.08 from last year’s $-0.85 per share. After $-0.84 actual EPS reported by Karyopharm Therapeutics Inc for the previous quarter, Wall Street now forecasts -8.33% EPS growth.

Karyopharm Therapeutics Inc (NASDAQ:KPTI) Ratings Coverage

Out of 11 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 10 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 91% are positive. Karyopharm Therapeutics Inc. has been the topic of 18 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The firm has “Hold” rating by Jefferies given on Wednesday, January 6. JP Morgan initiated the stock with “Overweight” rating in Wednesday, September 2 report. MLV maintained Karyopharm Therapeutics Inc (NASDAQ:KPTI) rating on Wednesday, August 12. MLV has “Buy” rating and $42 price target. Jefferies maintained the stock with “Hold” rating in Tuesday, March 15 report. As per Friday, May 27, the company rating was initiated by Raymond James. The firm has “Buy” rating given on Thursday, September 8 by H.C. Wainwright. As per Tuesday, August 11, the company rating was maintained by Leerink Swann. On Tuesday, December 22 the stock rating was initiated by Canaccord Genuity with “Buy”. On Monday, March 14 the stock rating was maintained by JP Morgan with “Overweight”. Bank of America downgraded it to “Underperform” rating and $11 target price in Tuesday, March 15 report.

According to Zacks Investment Research, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States.”

Insitutional Activity: The institutional sentiment increased to 1.54 in 2016 Q2. Its up 1.01, from 0.53 in 2016Q1. The ratio improved, as 11 funds sold all Karyopharm Therapeutics Inc shares owned while 15 reduced positions. 10 funds bought stakes while 30 increased positions. They now own 19.84 million shares or 5.28% less from 20.95 million shares in 2016Q1.
Moreover, Legal & General Grp Incorporated Public Limited has 0% invested in Karyopharm Therapeutics Inc (NASDAQ:KPTI) for 4,448 shares. Blackrock Institutional Na last reported 530,816 shares in the company. Tiaa Cref Investment Management Lc holds 0% of its portfolio in Karyopharm Therapeutics Inc (NASDAQ:KPTI) for 76,318 shares. Moreover, Thomas J Herzfeld has 0.02% invested in Karyopharm Therapeutics Inc (NASDAQ:KPTI) for 4,868 shares. Ubs Asset Management Americas last reported 10,500 shares in the company. Moreover, Jacobs Levy Equity Mgmt Inc has 0.01% invested in Karyopharm Therapeutics Inc (NASDAQ:KPTI) for 36,300 shares. Endurance Wealth Mngmt Incorporated holds 6,000 shares or 0.01% of its portfolio. Proshare Advsrs Limited has invested 0% of its portfolio in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Susquehanna Intl Llp has invested 0% of its portfolio in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Fmr Ltd Com accumulated 0% or 5.36M shares. Blackrock has invested 0% of its portfolio in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Millennium Mgmt Ltd Liability Company holds 0.01% or 714,104 shares in its portfolio. Nationwide Fund Advisors holds 0% or 21,258 shares in its portfolio. Fincl Bank Of New York Mellon accumulated 101,558 shares or 0% of the stock. Jpmorgan Chase & Com holds 0% of its portfolio in Karyopharm Therapeutics Inc (NASDAQ:KPTI) for 361,979 shares.

Insider Transactions: Since May 10, 2016, the stock had 0 insider purchases, and 10 sales for $3.86 million net activity. $801,806 worth of Karyopharm Therapeutics Inc (NASDAQ:KPTI) shares were sold by Chione Ltd.

Another recent and important Karyopharm Therapeutics Inc (NASDAQ:KPTI) news was published by which published an article titled: “Why Karyopharm Therapeutics Stock Is Falling Today” on September 06, 2016.

KPTI Company Profile

Karyopharm Therapeutics Inc., incorporated on December 22, 2008, is a clinical-stage pharmaceutical company. The Firm is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The Company’s segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Firm has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. The Company’s lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. The Firm is also engaged in the clinical development of selinexor in various solid tumor indications. The Firm has initiated various later-phase clinical trials to evaluate selinexor in hematological cancers and solid tumors. The Firm has also initiated a double-blinded, placebo-controlled, randomized Phase II/III study of single-agent selinexor in liposarcoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment